News
MIMETAS in the global news. Read more about our latest research, developments, collaborations, and product launches.
Sign up for our newsletter to stay up to date.
MIMETAS Expands Adult Stem Cell Organoid License to All Organs
Leiden, The Netherlands, May 3, 2022 – MIMETAS announces today that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.
Read more
MIMETAS participates in €325 million Oncode-PACT initiative to accelerate and improve oncology drug development
Leiden, April 14, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund.
Read more
MIMETAS attends AACR 2022 Conference in New Orleans
New Orleans, April 8-13, 2022 – MIMETAS recently attended the AACR Annual Meeting in person. The AACR Annual Meeting covers the latest discoveries across the spectrum of cancer research.
Read more
Modelling and prevention of acute kidney injury through ischemia and reperfusion in a combined human renal proximal tubule/blood vessel-on-a-chip
Leiden, February 24, 2022 – Scientists from MIMETAS and Astellas introduce a combined human renal proximal tubule/blood vessel-on-a-chip model in the OrganoPlate® 3-lane 40 to study acute kidney injury caused by renal ischemia/reperfusion injury. This article has just been published in Kidney360.
Read more
Phase 2 funding of £1 million awarded by CRACK IT Challenges to develop TDAR-on-a-chip
Leiden, February 22, 2022 – MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 2 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.
Read more
MIMETAS in TEDx: 'Why Organs-on-Chips raise the odds in drug development'
Leiden, February, 2022 – TEDxBoerhaavedistrictStudio guides us through a virtual ‘Walk in the Park’ with inspiring TEDx speakers from the Boerhaavedistrict in Leiden, The Netherlands. This month, Jos Joore (MIMETAS’ CEO) explains why the development of pharmaceuticals is a hugely expensive and uncertain process and offers a possible solution for more efficient drug development.
MIMETAS attends SLAS 2022 Conference in Boston, Massachusetts
Leiden, February 14, 2022 – MIMETAS has just attended the annual SLAS International Conference and Exhibition in person, which took place on February 5-9, 2022, in Boston, Massachusetts. This flagship conference connects great minds in life sciences and technology with each other and with the innovation, technology, and automation needed to transform research each year.
Read more
Organ-on-a-Chip technology for in vitro grafting and vascularisation of 3D tissues
Oegstgeest, January 3, 2022 – In 2019, MIMETAS was granted two-year funding and support by the SME instrument for the project 'OrganoPlate Graft'. The project resulted in the development of the first OrganoReady® Vascular bed: a ready-to-use OrganoPlate® Graft with pregrown vascular beds.
Read more
Microfluidic Platforms for Modelling Pancreatic Ductal Adenocarcinoma and as Translational Models for Drug Screening
Leiden, December 29, 2021 – Scientists from MIMETAS published an article on using microfluidic platforms for modelling and studying Pancreatic Ductal Adenocarcinoma and as translational models for drug screening. Their work was published in Frontiers in Cell and Developmental Biology.
Read more
Modeling ischemic stroke in a triculture neurovascular unit on-a-chip
Leiden, December 15, 2021 – Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain. This research has just been published in Fluids and Barriers of the CNS.
Read more
A novel in vitro membrane permeability methodology using three-dimensional Caco-2 tubules in a microphysiological system
Leiden, November 23, 2021 – Scientists from MIMETAS and Astellas introduce a new method to study in vitro drug permeability based on 3D Caco-2 tubules cultured in the OrganoPlate® 3 lane-40. This article has just been published in the Journal of Pharmaceutical Sciences.
Read more
Adoption of organ-on-chip platforms by the pharmaceutical industry
Leiden, October 13, 2021 – Our CEOs Paul Vulto and Jos Joore published a correspondence article about the adoption of organ-on-chip platforms by the pharmaceutical industry. This article has been published in Nature Reviews – Drug Discovery.
Read more
Intestinal Epithelium Tubules on a Chip
Leiden, September 15, 2021 – Scientists from MIMETAS introduce a method to culture intestinal epithelium tubules-on-a-chip in the OrganoPlate® 3 lane 40. This book chapter has just been published in Methods in Molecular Biology – Organ-on-a-chip Methods and Protocols.
Read more
A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease
Leiden, August 2, 2021 - Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throughput, artificial membrane-free microfluidic platform. The research has just been published in the International Journal of Molecular Sciences.
Read more
MIMETAS and Roche enter into a collaboration to develop human disease models for drug development
Leiden, July 6, 2021 - MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
Read more
Long-Lived Human Lymphatic Endothelial Cells to Study Lymphatic Biology and Lymphatic vessel/Tumor Coculture in a 3D Microfluidic Model
Leiden, June 29, 2021 - Scientists from MIMETAS and the UMC Utrecht introduce a new organ-on-a-chip lymphatic vessel model together with a novel long-lived lymphatic cell line to study the lymphatic system in health and disease. This research has been published in ACS Biomaterials Science & Engineering.
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations
Leiden & Tokyo, June 7, 2021 - MIMETAS has been awarded the ‘Deshima Business Award” in the category ‘Newly Established’ by the NCCJ, and the Embassy of the Kingdom of the Netherlands.
Read more
MIMETAS opens Phenotypic Screening Center
Leiden, May 27, 2021 - MIMETAS, the global leader in human-relevant organ-on-a-chip models, has just opened their Phenotypic Screening Center. The center facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques.
Read more
MIMETAS appoints Patrice Denèfle as Scientific Advisor
Leiden, April 22, 2021 - MIMETAS, the global leader in organ-on-a-chip-based disease modeling, is happy to announce the appointment of Patrice Denèfle as their Scientific Advisor. Patrice brings in longstanding scientific expertise and an extensive network in the pharmaceutical industry. His involvement will support the therapeutic research strategy and spark new collaborations with leading pharmaceutical companies based on MIMETAS’ phenotypic modeling and screening capabilities.
Read more
TEER measurements on perfused membrane-free epithelia
Leiden, April 16, 2021 - Scientists from MIMETAS, Sciospec and Leiden University introduce an instrument that measures TransEpithelial Electrical Resistance (TEER) of perfused epithelial tubes in the microfluidic OrganoPlate® platform. The research is recently published in the Journal Lab on a Chip.
Read more
Robust and versatile renal tubule-on-a-chip for nephrotoxicity assessment
March 31, 2021 – MIMETAS, Roche Innovation Center, Pfizer, GlaxoSmithKline (GSK), Utrecht Institute for Pharmaceutical Sciences, University of Applied Sciences Northwestern Switzerland, and the Swiss Centre for Applied Human Toxicology, developed a high throughput, 3D microfluidic platform (Nephroscreen) to detect drug-induced nephrotoxicity.
Read more
£900k awarded by CRACK IT Challenges to develop TDAR-on-a-chip
February 9, 2021 – MIMETAS has been awarded by NC3Rs' CRACK IT Challenges competition with Phase 1 funding for the development of a human in vitro T-cell dependent antibody response (TDAR) assay.
Read more
3D-cember 2020: videos of talks now on-demand
December 10, 2020 – To put new developments in 3D tissue biology in the limelight, MIMETAS organizes 3D-cember every 3rd of December. Videos of the 2020 live-streamed edition are now available on-demand.
MIMETAS launches assay ready product line for Organ-on-a-Chip
March 3, 2020 – Innovative in vitro models ready-to-use for safety, ADME, and toxicology studies in drug development and food & nutrition research.
Read more
Snake Venom Gland Organoids
January 23, 2020 – The Hubrecht institute and MIMETAS investigated if venom molecules produced by snake venom gland organoids also function as actual venom using the OrganoPlate® platform.
MIMETAS and Hubrecht Organoid Technology to develop and market Organoids-on-a-Chip
October 1, 2019 – MIMETAS and Hubrecht Organoid Technology (HUB) entered into a strategic collaboration to market organoid models on a chip.
Read more
Adult Stem Cell-Derived Kidney-on-a-Chip in Nature Biotechnology
March 5, 2019 – Leading stem cell research group and global leader in organ-on-a-chip technology develop stem cell-derived kidney tubules in microfluidic chips.
MIMETAS Secures 20 Million Dollar Series B Financing
April 11, 2018 – Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new product development.
MIMETAS in consortium to develop in vitro placenta models
March 17, 2018 – MIMETAS in a consortium to develop in vitro placenta models.
Read more
MIMETAS partner in €4.5mn EU Interreg project BIOMAT
January 1, 2018 – MIMETAS is partner of the Interreg project 'Biomat' aiming to develop a platform for high-throughput testing of biomaterials in a physiologically relevant environment on-a-chip.
Read more
MIMETAS raises 5.2 million dollar for organ-on-a-chip
October 8, 2014 – MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology.
Read more
